For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Dana-farber-cancer Institute Inc.

USPTO Granted Patents = 1,207

CIPO Patents = 65

EPO Patents = 301

Trademarks = 37

Forward Citations = 10,755

Loading Chart...

Loading Chart...

1,365 inventors (with patents filed for the assignee):

Nathanael Schiander Gray (140 out of 173 patents)

Gordon James Freeman (80 out of 90 patents)

James Elliott Bradner (60 out of 61 patents)

4. Loren D Walensky (52 out of 53 patents)

5. Wayne A Marasco (52 out of 55 patents)

6. Donald W Kufe (49 out of 59 patents)

7. Tinghu Zhang (46 out of 48 patents)

8. Bruce M Spiegelman (38 out of 42 patents)

9. Jun Qi (36 out of 36 patents)

10. Hwan Geun Choi (32 out of 51 patents)

11. Pasi Antero Janne (32 out of 32 patents)

12. Joseph G Sodroski (32 out of 33 patents)

13. Matthew Meyerson (31 out of 31 patents)

14. Kenneth Carl Anderson (30 out of 38 patents)

15. Glenn Dranoff (28 out of 30 patents)

Core Competencies:

Cancer Vaccines

Protein Degradation

Chromatin Remodeling

T Cell Receptors

Kinase Inhibitors

EGFR Inhibitors

Biomarkers

Nucleic Acid Constructs

Antibody Therapeutics

CRISPR Systems

Anemia Treatment

MicroRNA Signatures

1,207 patents: Sort by Forward Citations

1. 12491251 - Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof (2025-12-09),

2. 12479852 - Compounds, compositions, and methods for protein degradation (2025-11-25),

3. 12479847 - Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 (2025-11-25),

4. 12478665 - Cancer vaccine compositions and methods for using same to prevent and/or treat cancer (2025-11-25),

5. 12473334 - SWI/SNF family chromatin remodeling complexes and uses thereof (2025-11-18),

6. 12466809 - CDK2/5 degraders and uses thereof (2025-11-11),

7. 12454572 - Methods of treating anemia in myelodysplastic syndromes (2025-10-28),

8. 12448462 - Antibodies against MUC1 (2025-10-21),

9. 12448429 - T cell receptors specific to b-cell maturation antigen for treatment of cancer (2025-10-21),

10. 12441775 - BCL-W polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss (2025-10-14),

11. 12441685 - Compounds and methods for treating cancer (2025-10-14),

12. 12440451 - Compositions and methods using an epigenetic inhibitor (2025-10-14),

13. 12435377 - Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins (2025-10-07),

14. 12435372 - Methods for profiling the T-cell-receptor repertoire (2025-10-07),

15. 12433803 - Methods and compositions for studying cell evolution (2025-10-07),

Dana-Farber Cancer Institute is a world-renowned non-profit organization dedicated to providing expert, compassionate care to cancer patients while conducting groundbreaking research to find cures and preventions for all types of cancer. With a team of highly skilled oncologists, scientists, and healthcare professionals, Dana-Farber works tirelessly to improve the lives of those affected by cancer and strives for excellence in patient care, education, and clinical research.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

1,207 Patents

#5 in Boston, MA

#21 in Massachusetts

#410 in US

#813 in the World

Boston, MA, United States of America

Dana-farber-cancer Institute Inc.

Forward Citations = 10,755

1,365 inventors:

Nathanael Schiander Gray (140 out of 173 patents)

Gordon James Freeman (80 out of 90 patents)

James Elliott Bradner (60 out of 61 patents)

4. Loren D Walensky (52 out of 53 patents)

5. Wayne A Marasco (52 out of 55 patents)

Please report any incorrect information to support@idiyas.com

Loading…